Healthy Life

According to the American Cancer Society there are around 13,000 newly registered cases of this form of leukemia every year in North America. This form of leukemia affects more adults than children. The disease occurs when the myeloblasts do not mature into different blood cells. So, how about the leukemia AML prognosis according to now a day’s technology?

Like all other types of leukemia, a diagnosis of AML begins with a physical examination. There could be swelling to the lymph nodes, liver, or the spleen . A blood test will be done to determine if you have anemia and a low level of platelets . The final test that will be conclusive is a biopsy of the bone marrow.

When the AML has been diagnosed it is then classified as one of eight subtypes which is dependent on the appearance of the cell. It is then further classified into French-American-British (FAB) sub types. Identifying the classification of the disease is of the utmost importance as the different sub-types respond to different treatments.

AML Classsification after Leukemia AML Prognosis

When the leukemia has been diagnose, there are eight subtypes into which it can be classified, based on the cells’ appearance. The disease is then further classified into subtypes. The reason being that different sub-groups and types of leukemia respond to different treatments. The identification disease’s FAB classification is important.

There are nine different FAB subtypes of acute myelogenous leukemia all beginning with the letter M:

• 0: undifferentiated AML

• 1: Acute myelogenous leukemia with minimal cell maturation

• 2: Acute myelogenous leukemia with abnormal cell maturation

• 3: APL

• 4: AML

• 4 eos: M4 with eosinophilia.

• 5: Acute monocytic leukemia

• 6: AEL

• 7: Acute megakaryoblastic leukemia.

There is another classification that was developed by the World Health Organization (WHO) intended to replace the FAB. It divides the AML into five categories.

• Acute myelogenous leukemia due to radiation or chemotherapy

• Acute myelogenous leukemia with genetic abnormalities

• Acute myelogenous leukemia with more than one myeloid cell present)

• Acute myelogenous leukemia not otherwise specified

The proposal from the WHO has not yet replaced FAB as the classification used most commonly.
The WHO proposal has yet to replace FAB as the most common AML classification system.

Acute Myelogenous Leukemia AML Prognosis and AML Survival Rate

Prompt treatment increases a patient’s potential leukemia survival rate. According to Merck Pharmaceuticals (2008), approximately 50 to 85 percent of treated cases result in remission — defined as the reduction or disappearance of cancer symptoms.

Overall, 20 to 40 percent of people who go into remission are free of symptoms five years later. Acute myelogenous leukemia survival rates rise to 40 and 50 percent for younger people who receive stem cell transplants. If a patient hasn’t relapsed after five years of remission, he’s considered cured.

Certain factors affect leukemia AML prognosis. Factors that may worsen a patient’s leukemia survival rate include:

• Advanced age

• High white blood cell count at the time of diagnosis

• History of prior leukemia.

Chromosomal alterations can also affect leukemia survival rate, although this role is complicated. While some chromosomal alterations may worsen the prognosis, others may improve the chances of remission or even cure in cases of acute myelogenous leukemia.